文献速递核素与放射性配体治疗肿瘤 PET/CT

225Ac-与177Lu-PSMA-617串联同位素治疗在前列腺癌小鼠模型中的研究

Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer.
PubMed 文献 · J Nucl Med · 2023-10-05

在播散性前列腺癌小鼠模型中,比较225Ac-与177Lu-PSMA-617单用及串联治疗的疗效。显微镜下病变阶段,225Ac单用及串联均显著延缓肿瘤生长并延长生存,177Lu单用无效;肉眼可见病变阶段,所有治疗组均有效,225Ac单用与串联无显著差异。

要点

  • 35 MBq 177Lu与40 kBq 225Ac在皮下C4-2模型中产生等效肿瘤吸收剂量。
  • 接种后3周(显微镜下病变)治疗:225Ac单用及串联显著延缓肿瘤生长并延长生存,177Lu单用与未治疗无显著差异。
  • 接种后5周(肉眼可见病变)治疗:所有治疗组均延缓肿瘤生长并改善生存,225Ac单用与串联无显著差异。

核心结论

  • 在播散性前列腺癌小鼠模型中,225Ac与177Lu-PSMA-617同时给药较177Lu单用显著降低肿瘤生长,而177Lu单用对显微镜下病变无效。
  • 在疾病进展后期携带肉眼可见毫米级病变的小鼠中,177Lu和225Ac的单同位素及串联方案均显著延缓肿瘤生长并带来生存获益。
  • 尽管225Ac单药观察到最大获益,但串联组在疾病负担或生存获益方面无显著差异,提示串联组中降低的225Ac活度得到了充分补偿。
  • 该模型中225Ac的 superior 疗效提示在显微镜下病变情况下可能优先选择α发射体单用或联合使用。

研究设计与样本

  • 研究在播散性前列腺癌小鼠模型中进行,直接比较α粒子与β粒子治疗及两者联合在不同疾病阶段的疗效。
  • 首先在C4-2皮下肿瘤荷瘤NSG小鼠中于治疗后5个时间点进行离体生物分布研究,以确定177Lu-和225Ac-PSMA-617的可比注射活度。
  • 为建立更具代表性的转移性前列腺癌模型,将表达荧光素酶的C4-2细胞接种至NSG小鼠左心室,导致播散性内脏和骨病变。
  • 在接种后3周或5周,小鼠接受等效肿瘤剂量沉积活度的177Lu-或225Ac-PSMA-617单用或联合治疗(35 MBq 177Lu、40 kBq 225Ac,或17 MBq 177Lu + 20 kBq 225Ac;每组10只)。
  • 通过每周生物发光成像评估疾病负担,以全身肿瘤负担和总生存评估疗效。

主要发现

  • 离体生物分布研究显示,在皮下C4-2模型中35 MBq 177Lu与40 kBq 225Ac产生等效的肿瘤吸收剂量。
  • 接种后3周(显微镜下病变)接受177Lu治疗的小鼠疾病负担与未治疗小鼠无显著差异。
  • 接种后3周,225Ac-PSMA-617单用及与177Lu联合(17 MBq 177Lu + 20 kBq 225Ac)均与显著的全身体肿瘤生长迟缓和生存获益相关(总生存:未治疗8.3周,177Lu 9.4周,225Ac单用15.3周,串联治疗14.1周)。
  • 接种后5周(肉眼可见病变)治疗时,所有治疗组均显示肿瘤生长迟缓和生存改善,225Ac单用与联合半数225Ac活度及177Lu的串联方案之间无显著差异(总生存:未治疗7.9周,177Lu 10.3周,225Ac单用14.6周,串联治疗13.2周)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is a promising option for metastatic castration-resistant prostate cancer. Clinical experience using 177Lu or 225Ac has demonstrated encouraging treatment responses; however, responses are not durable. Dual-isotope combinations, or "tandem" approaches, may improve tolerability while retaining a high tumor dose. In this study, we directly compared α- versus β-particle treatment, as well as a combination thereof, at different stages of disease in a murine model of disseminated prostate cancer. Methods: First, to determine comparable injected activities from 177Lu- and 225Ac-PSMA-617, ex vivo biodistribution studies were performed at 5 time points after treatment of C4-2 subcutaneous tumor-bearing NSG mice. To establish a more representative model of metastatic prostate cancer, NSG mice were inoculated with luciferase-expressing C4-2 cells in the left ventricle, leading to disseminated visceral and bone lesions. At either 3 or 5 wk after inoculation, the mice were treated with equivalent tumor dose-depositing activities of 177Lu- or 225Ac-PSMA-617 alone or in combination (35 MBq of 177Lu, 40 kBq of 225Ac, or 17 MBq of 177Lu + 20 kBq 225Ac; 10/group). Disease burden was assessed by weekly bioluminescence imaging. Treatment efficacy was evaluated using whole-body tumor burden and overall survival. Results: The ex vivo biodistribution studies revealed that 35 MBq of 177Lu and 40 kBq of 225Ac yield equivalent absorbed tumor doses in a subcutaneous C4-2 model. The disease burden of mice treated at 3 wk after inoculation (microscopic disease) with 177Lu was not significantly different from that of untreated mice. However, 225Ac-PSMA-617 both as a single agent and in combination with 177Lu (17 MBq of 177Lu + 20 kBq of 225Ac) were associated with significant whole-body tumor growth retardation and survival benefit (overall survival, 8.3 wk for nontreatment, 9.4 wk for 177Lu, 15.3 wk for 225Ac alone, and 14.1 wk for tandem therapy). When treated at 5 wk after inoculation (macroscopic disease), all treatment groups showed retarded tumor growth and improved survival, with no significant differences between 225Ac alone and administration of half the 225Ac activity in tandem with 177Lu (overall survival, 7.9 wk for nontreatment, 10.3 wk for 177Lu, 14.6 wk for 225Ac alone, and 13.2 wk for tandem therapy). Conclusion: Treatment of a disseminated model of prostate cancer with simultaneous 225Ac- and 177Lu-PSMA-617 results in significantly decreased tumor growth compared with 177Lu, which was ineffective as a single agent against microscopic lesions. Mice treated later in the disease progression and bearing macroscopic, millimeter-sized lesions experienced significant tumor growth retardation and survival benefit in both monoisotopic and tandem regimens of 177Lu and 225Ac. Although the greatest benefits were observed with the single agent 225Ac, the tandem arm experienced no significant difference in disease burden or survival benefit, suggesting that the reduced activity of 225Ac was adequately compensated in the tandem arm. The superior therapeutic efficacy of 225Ac in this model suggests a preference for α-emitters alone, or possibly in combination, in the microscopic disease setting.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Meyer C, Stuparu A, Lueckerath K, et al. Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer. J Nucl Med. 2023. PMID: 37797974. doi:10.2967/jnumed.123.265433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。